Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026-2035.

Rosenstock, Julio; Aronson, Ronnie; Grunberger, George; Hanefeld, Markolf; Piatti, PierMarco; Serusclat, Pierre; Cheng, Xi; Zhou, Tianyue; Niemoeller, Elisabeth; Souhami, Elisabeth; Davies, Melanie

Rosenstock, Julio; Aronson, Ronnie; Grunberger, George; Hanefeld, Markolf; Piatti, PierMarco; Serusclat, Pierre; Cheng, Xi; Zhou, Tianyue; Niemoeller, Elisabeth; Souhami, Elisabeth; Davies, Melanie.

Diabetes Care ; 40(6): 809, 2017 06.

Article em En | MEDLINE | ID: mdl-28420696

Texto completo

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439410
https://dx.doi.org/10.2337/dc17-er06c

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439410
https://dx.doi.org/10.2337/dc17-er06c

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article